Gan&Lee Pharmaceuticals dosed the first of 112 planned participants in a multicenter, randomized, double-blind, placebo-controlled Phase 1 trial of GZC8072 tablets on 9 September 2026 as reported by Prnewswire. The study, registered as CTR20263271, evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics as its primary endpoints.

This first-in-human randomized controlled trial moves GZC8072 from proprietary formulation work into human evaluation. The n=112 design includes single ascending dose cohorts in healthy adults and multiple ascending dose cohorts in participants with overweight or obesity. No efficacy data exist. The evidence stage is Phase 1. The study must establish a baseline half-life and adverse event profile before any trial targeting glycemic control or weight reduction can begin.

Phase 1 trial design and endpoints

The single ascending dose arm evaluates the compound in healthy volunteers. The multiple ascending dose arm examines repeated exposure in people with overweight or obesity, a population resembling the intended treatment group for a GLP-1 receptor agonist. Primary endpoints focus on safety and pharmacokinetics. Secondary pharmacodynamic measures may inform receptor engagement, but the registry data released through PR Newswire does not specify which biomarkers will be tracked.

Gan&Lee positions GZC8072 as a once-weekly oral peptide as reported by Biospace. That dosing interval would differ from daily oral GLP-1 receptor agonists already under investigation. Weekly oral dosing could differentiate GZC8072 from currently approved daily oral GLP-1 therapies, while retaining a peptide-based pharmacology distinct from small-molecule agonists such as orforglipron as reported by Allsci. The company attributes the extended half-life to its NovaPeptide platform and the oral delivery profile to its SupOraTide platform as reported by Allsci. Both remain unproven in human subjects.

Receptor affinity and half-life extension claims from preclinical work do not constitute clinical evidence. The Phase 1 trial will generate the first in vivo human pharmacokinetics data for this compound.

Formulation platforms and evidence boundary

NovaPeptide is described as a technology intended to extend peptide half-life and support manufacturing. SupOraTide is designed to improve oral bioavailability as reported by Allsci. Neither platform has published peer-reviewed human data in the supplied source set. The distinction between a formulation claim and a demonstrated clinical property matters when Chinese, European, and North American regulators evaluate oral peptide candidates that must cross gastrointestinal barriers before reaching systemic circulation.

The oral GLP-1 field includes small-molecule programs and peptide-based approaches with varying dosing schedules. While aleniglipron has demonstrated durable, clinically meaningful and competitive weight reduction alongside a promising long-term safety and tolerability profile as a once-daily oral GLP-1 program as reported by BioSpace, GZC8072 aims for a once-weekly schedule. The central formulation problem is explained in our guide to oral peptide delivery and bioavailability.

Regulatory questions surrounding the retatrutide fda classification appeal continue to shape how peptide therapeutics are categorized. The broader comparison of multi receptor incretin peptides provides context for where single-receptor agonists like GZC8072 fit within incretin pharmacology.

The 112-participant cohort is planned. Final enrollment figures, completion dates, and any adverse event profile results remain unresolved. The claim that GZC8072 is ultra-long-acting is a corporate assertion. The Phase 1 data will determine whether the once-weekly dosing interval holds up under controlled measurement of half-life and exposure in human subjects.

The company announced the dosing milestone via a 9 September 2026 press release, and no subsequent regulatory or registry updates have altered the trial parameters as reported by Philippinetimes.